ARTICE® Therapy
Bacterial Sepsis
Phase 2Active
Key Facts
About Artcline
Artcline GmbH, founded in 2007 and based in Munich, is a clinical-stage biotechnology company pioneering an immune cell-based extracorporeal therapy for bacterial sepsis. Its lead program, the patented ARTICE® Therapy, is undergoing final clinical validation in a controlled randomized multicenter study in Germany (ReActIF-ICE), having already obtained initial regulatory approvals. The company is led by a seasoned management team with deep expertise in immunology, biopharmaceuticals, and medical device development, aiming to address a significant unmet medical need with high associated healthcare costs.
View full company profile